Table 2 Response rates
Total N = 538 | DRd N = 224 | E-IRd N = 104 | L-IRd N = 67 | KRd N = 143 | p-value1 | |
|---|---|---|---|---|---|---|
Maximal treatment response | ||||||
sCR, CR | 38 (8.1%) | 12 (6.5%) | 12 (12.2%) | – | 14 (10.4%) | |
VGPR | 223 (47.8%) | 113 (60.8%) | 28 (28.6%) | 12 (25.0%) | 70 (51.9%) | |
PR | 142 (30.4%) | 45 (24.2%) | 38 (38.8%) | 22 (45.8%) | 37 (27.4%) | |
MR | 31 (6.6%) | 6 (3.2%) | 10 (10.2%) | 7 (14.6%) | 8 (5.9%) | |
SD | 21 (4.5%) | 8 (4.3%) | 7 (7.1%) | 4 (8.3%) | 2 (1.5%) | |
PD | 12 (2.6%) | 2 (1.1%) | 3 (3.1%) | 3 (6.2%) | 4 (3.0%) | |
Unknown | 71 | 38 | 6 | 19 | 8 | |
Overall Response Rate (PR or better) | < 0.001 | |||||
No | 64 (13.7%) | 16 (8.6%) | 20 (20.4%) | 14 (29.2%) | 14 (10.4%) | |
Yes | 403 (86.3%) | 170 (91.4%) | 78 (79.6%) | 34 (70.8%) | 121 (89.6%) | |
Unknown | 71 | 38 | 6 | 19 | 8 | |
Clinical Benefit Rate (MR or better) | 0.053 | |||||
No | 33 (7.1%) | 10 (5.4%) | 10 (10.2%) | 7 (14.6%) | 6 (4.4%) | |
Yes | 434 (92.9%) | 176 (94.6%) | 88 (89.8%) | 41 (85.4%) | 129 (95.6%) | |
Unknown | 71 | 38 | 6 | 19 | 8 | |